Novel Analog of Atrial Natriuretic Peptide Selective for Receptor-A Produces Increased Diuresis and Natriuresis in Rats

Hongkui Jin, Bing Li, Brian Cunningham, Jeffrey Tom, Renhui Yang, Patricia Sehl, G. Roger Thomas, Annie Ko, David Oare, and David G. Lowe

Departments of Cardiovascular Research, Protein Engineering and Bioorganic Chemistry, Genentech, Inc., South San Francisco, California 94080

Abstract

Atrial natriuretic peptide (ANP) binds to natriuretic peptide receptor-A (NPR-A), a membrane guanylyl cyclase, and to natriuretic peptide receptor-C (NPR-C), which plays a role in peptide clearance. Rat ANP (rANP) mutants that bind rat NPR-A selectively over rat NPR-C were isolated from randomized libraries of rANP-display phage by differential panning. One variant was identified with reduced NPR-C binding; rANP (G16R, A17E, Q18A) [rANP(REA18)]. Synthetic rANP(REA18) was equipotent with rANP in stimulating cGMP production from cloned rat NPR-A (ED50 = 1.8 nM) and was reduced in NPR-C binding by ~200-fold. When infused into conscious rats at 0.325 µg/min for 30 min rANP elicited an identical decrease in blood pressure compared with 0.25 µg/min of rANP(REA18), however the natriuretic (P < 0.05) and diuretic (P = 0.07) responses to rANP(REA18) were greater. These data are consistent with a role for NPR-C as a local decoy receptor attenuating NPR-A effects in the kidney, where these receptors are co-expressed. Improved NPR-A specificity could provide more effective natriuretic peptides for treatment of acute renal failure or heart failure. (J. Clin. Invest. 1996. 98:969–976.)

Key words: atrial natriuretic peptide • phage display • cGMP • natriuresis • diuresis

Introduction

Atrial natriuretic peptide (ANP),1 a circulating hormone derived principally from cardiac atrial myocytes, plays a role in the control of salt and water homeostasis and blood pressure (1–3). The effects of ANP on blood pressure and fluid balance are mediated through antagonism of angiotensin and vasopressin and the renin–angiotensin–aldosterone system (1, 4).

In addition, ANP is a vasodilator and also has direct actions on the kidney including increased glomerular filtration, inhibition of sodium reabsorption, and redistribution of renal blood flow to promote natriuresis and diuresis (1, 4).

For several of the responses to ANP, including increased glomerular filtration, natriuresis, and direct vasorelaxation (1, 4–6), there is evidence that cGMP is the intracellular second messenger of hormone action. Two ANP receptors have been cloned and expressed to date. One of the these, natriuretic peptide receptor-A (NPR-A), also known as guanylyl cyclase-A (GC-A), is a membrane enzyme that synthesizes cGMP in response to extracellular ligand binding (7, 8). Localization of the mRNA encoding this receptor by Northern blotting and in situ hybridization shows that the most abundant expression is in major target organs for ANP action, including the kidney, adrenal, and pituitary (8–10).

The second ANP receptor, NPR-C, is also a type-I membrane protein homologous to NPR-A in the extracellular domain, but has only a short cytoplasmic region of 37 amino acids (11). NPR-C is thought to principally mediate the metabolic clearance of ANP (12, 13). Other work has suggested that NPR-C plays a role in signal transduction (14), but this receptor is apparently not directly involved in the adrenal, renal, or cardiovascular actions of ANP. Expression of NPR-C has been described in a variety of tissues (14) including the kidney glomerulus (9, 15), where it is coexpressed with NPR-A. The pattern of NPR-C expression is not identical to NPR-A. The kidney, adrenal, lung, and heart are tissues where both receptors have been identified, but abundant colocalization is only prominent in the kidney glomerulus, whereas the pituitary and vascular smooth muscle apparently express much less NPR-C than NPR-A (9, 10, 14).

Research on the structure–activity relationships of ANP have focused on improving the molecules pharmacological properties. ANP variants with longer half-life and improved receptor specificity may be clinically useful for the treatment of renal failure, hypertension, and congestive heart failure (1, 4). Only recently, however, have ANP analogs specific for NPR-A, with no binding to NPR-C, been developed (16). Compounds with NPR-A selectivity would be expected to have a decreased metabolic clearance rate and longer half-life resulting in enhanced potency (17, 18). There is also the potential for enhanced responsiveness in the kidney, where coexpression of NPR-C and NPR-A may result in an attenuated NPR-A response due to receptor competition for ligand (16).

Although this hypothesis is supported by in vitro cell culture data, there is no direct in vivo pharmacological evidence to suggest that NPR-A selectivity will provide an improved renal response. Investigating the in vivo advantages to NPR-A selectivity have been hampered by the species specificity of the currently available analog for the human receptor, which has significantly reduced affinity for rat NPR-A (16).

We describe here the identification of a rat NPR-A selective ANP analog by competitive panning of mutant ANP phage
display libraries for sequences that bind preferentially to rat NPR-A in the presence of competing rat NPR-C. Analysis of the in vitro and in vivo pharmacology of this novel ANP analog suggests that specific targeting of NPR-A could be an effective clinical strategy for modulating renal function.

Methods

Receptor expression. Cloning and expression of the rat NPR-C (rNPR-C) cDNA as an extracellular domain-IgG Fc fusion protein (rC-IgG) has been described (19). Full-length rat NPR-C was expressed in human (h) kidney 293 cells as previously described for hNPR-C (16). For rNPR-A (7) the extracellular domain coding region was fused to the Fc portion of human IgG to produce the expression construct p.rA-IgG in direct analogy to the human fusion protein (20). For soluble receptor production, stable cell lines were seeded with construction p.rA-IgG in direct analogy to the human fusion protein (20).

Membrane preparation. Stable 293 cell lines expressing rat NPR-A(22) or rat NPR-C were removed from cell culture dishes with 0.5 mM Hepes, 5 mM MgCl₂, 100 mM NaCl, 0.7 mg/ml pepstatin A, 0.5 mg/ml leupeptin and 1 mM PMSF, pH 7.4. Homogenized using a poltron (Brinkman Instruments, Inc., Westbury, NY) at setting 5 for 30 s, then centrifuged at 400 g for 10 min at 4°C. The supernatant was collected and centrifuged at 100,000 X g for 30 min at 4°C. The membrane pellet was disrupted using a 7 ml Kontes Dounce tissue grinder (Fisher Scientific, Pittsburgh, PA) in storage buffer (50 mM Heps, 0.1 mM EDTA, 5 mM MgCl₂, 100 mM NaCl, 0.7 mg/ml pepstatin A, 0.5 mg/ml leupeptin and 1 mM PMSF, pH 7.4) and aliquots were frozen on dry ice before storage at −80°C.

Protein concentration was determined using a protein assay (Bio-Rad Laboratories, Richmond, CA) with IgG as a standard.

Membrane competition binding assays. Membranes diluted in 50 mM Heps, 5 mM MgCl₂, 0.1 M NaCl, 0.1 mM EDTA, 0.2% BSA, pH 7.4 were added to 96-well polypropylene plates (Sigma Chemical Co., St. Louis, MO) with an equal volume containing unlabeled competing peptide and 30 pmol [3H]-I-ANP (3,000 Ci/mmol, Amersham Corp., Arlington Heights, IL), and incubated for 2 h at 22°C. Bound peptide was separated from free by vacuum filtration through 1% polyethyleneimine-treated Packard unifilter-96 GF/B filter plates using a Packard Filtermate 196 cell harvester (Packard Instrument Co., Meriden, CT). The plates were washed six times with PBS, air dried before adding scintillant and counted in a Packard Topcount scintillation counter for 1 min/well. Binding was measured in duplicate for each concentration of competitor.

Concentration response of cGMP production. A stable 293 rNPR-A cell line (22) was used to determine natriuretic peptide agonist potencies. Peptide treatments and cGMP radioimmunoassay (Biomedical Technologies, Inc., Stoughton, MA) were carried out essentially as described (22, 24). All stimulations were performed in triplicate and samples were measured in duplicate for cGMP.

Data analysis. The competition binding curves and cGMP concentration responses were analyzed by the four-parameter logistic equation with the KaleidaGraph program (Synergy Software, Inc., Reading, PA) to obtain estimates of the IC₅₀ or EC₅₀ values. The non-linear least-squares curve fitting program LIGAND (25) was used to analyze the competition binding curves.

Animals. Male Sprague-Dawley (SD) rats (8-wk of age; Charles River Breeding Laboratories, Inc., Wilmington, MA) were acclimated to the facility for at least 1 wk before surgery, fed a pelleted rat chow and water ad libitum, and housed in a light and temperature controlled room. The experimental procedures, which were approved by Genentech’s Institutional Animal Care and Use Committee, conformed to the guiding principles of the American Physiological Society.

Vasoconstriction experiments. Rings of thoracic aorta were prepared from 350–400-gram rats. Each rat was anesthetized with 60 mg/kg (p.o.) pentobarbital sodium (Abbott Laboratories, North Chicago, IL) and following thoracotomy the aorta was removed and placed in Krebs–Henseleit solution, containing 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.6 mM MgSO₄, 25 mM NaHCO₃, 1.2 mM KH₂PO₄, and 5.5 mM glucose, and gassed with 95% O₂/5% CO₂. Any associated connective tissue was trimmed and the aorta cut into 2–3 mm-wide rings which were suspended in 15 ml organ baths under 1.5 grams of tension. After 20 min of equilibration, during which the bathing solution was constantly exchanged, the tissue was submaximally preconstricted with phenylephrine (5 x 10⁻⁸ M). The presence of endothelium was confirmed by vasodilator responses to acetylcholine (1 x 10⁻⁴ M) (26). Following washout and subsequent preconstriction, cumulative dose–response curves to the vasodilatory effects of either ratANP or rANP(REA18) were constructed in each tissue. All responses were measured using Grass FT03 isometric strain gauges coupled to a model 79D Grass polygraph (Grass Instrument Co.,
Figure 1. Sequence of rANP and rANP(REA18). The amino acid sequence of the 28 residue rat ANP is shown in signal letter code with the disulfide bond indicated by a line connecting C7 to C23. Dashes indicate identical residues for rANP(REA18) compared with rANP.

Quincy, MA). Phenylephrine hydrochloride (Sigma Chemical Co.) was dissolved as 1 mg/ml stock solution in 0.9% (wt/vol) saline solution containing 1 mg/ml sodium ascorbate. rANP and rANP(REA18) were dissolved as 10 μM stock solutions in PBS.

Surgery. Rats were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) (Aveco Co., Inc., Fort Dodge, IA) and xylazine (10 mg/kg); (Rugby Laboratories, Inc., Rockville Center, NY). A catheter (PE-10 fused with PE-50) filled with heparin saline solution (10 mg/kg) was implanted into the abdominal aorta via the right femoral artery for measurement of mean arterial pressure (MAP) and heart rate (HR). A second catheter was inserted into the right femoral vein for intravenous infusions. The catheters were exteriorized and fixed at the back of the neck. To reduce the capacity of the bladder, 75% of the bladder was excised from cells expressing recombinant rNPR-C or rNPR-A. rANP(REA18) inhibits binding on cloned rNPR-C with an IC_{50} = 10 nM, compared to IC_{50} = 58

Table I. Kinetic Constants for NEP Degradation of Peptides

<table>
<thead>
<tr>
<th>Peptide</th>
<th>ng NEP</th>
<th>Reaction time</th>
<th>K_{in}</th>
<th>V_{max}</th>
<th>k_{cat}</th>
<th>k_{cat}/K_{in}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>min</td>
<td>μM</td>
<td>μmol/min per mg</td>
<td>min^{-1}</td>
<td>μM^{-1} min^{-1}</td>
<td></td>
</tr>
<tr>
<td>rANP(REA18)</td>
<td>75</td>
<td>18</td>
<td>19.5</td>
<td>0.4</td>
<td>34.0</td>
<td>1.7</td>
</tr>
<tr>
<td>rANP(REA18)</td>
<td>75</td>
<td>18</td>
<td>22.1</td>
<td>0.4</td>
<td>33.4</td>
<td>1.5</td>
</tr>
<tr>
<td>rANP(REA18)</td>
<td>150</td>
<td>18</td>
<td>30.4</td>
<td>0.5</td>
<td>42.2</td>
<td>1.4</td>
</tr>
<tr>
<td>rANP</td>
<td>75</td>
<td>18</td>
<td>120.5</td>
<td>2.9</td>
<td>256.8</td>
<td>2.1</td>
</tr>
<tr>
<td>rANP</td>
<td>75</td>
<td>12</td>
<td>142.2</td>
<td>4.3</td>
<td>384.6</td>
<td>2.7</td>
</tr>
</tbody>
</table>

Results

Mutant ANP selective for rat NPR-A. To develop an ANP variant selective for rNPR-A we used the previously described method of differential panning with libraries of mutant ANP display phage in which segments of 3–4 codons in ANP were completely randomized (16). In this work, we found that specificity mutations conferring hNPR-A selectivity occurred only in the 17 amino acid disulfide bonded ring of hANP. Based on this result, we constructed four libraries of mutant rANP display phage that contained random mutations within the ring, and subjected them to seven rounds of differential panning with immobilized rA-IgG in competition with solution phase rC-IgG. The best receptor-selective rANP sequence identified contained three mutations, G16R, A17E, and Q18A [designated rANP(REA18)] (Fig. 1). An analysis of binding affinities by phage-ELISA showed that these variant phagemids were ~130-fold reduced in affinity for rNPR-C yet retained wild-type affinity for rNPR-A.

Synthesis of rANP(REA18) allowed us to confirm that receptor selectivity was retained in the free peptide. Solution equilibrium binding studies were performed with membranes from human embryonic kidney 293 cells that express recombinant rNPR-C or rNPR-A. rANP(REA18) inhibits 125I-rANP binding to rNPR-C with an IC_{50} = 10 nM, compared to IC_{50} = 58
972  Jin et al.

pM for rANP (Fig. 2). rANP bound to rNPR-A with IC$_{50}$ = 237 pM (Fig. 3). With this receptor rANP(REA18) had a slightly reduced affinity with IC$_{50}$ = 438 pM. On average the binding was approximately two to fivefold reduced to NPR-A. The concentration response for cGMP stimulation on rNPR-A expressing cell lines showed both molecules to be essentially equipotent, with ED$_{50}$'s of 1.80 and 1.87 nM for rANP and rANP(REA18), respectively (Fig. 3).

Neutral endopeptidase assay. To determine if rANP(REA18) was significantly different than rANP in its sensitivity to NEP degradation we measured the kinetic parameters of NEP on these two substrates. Table I summarizes the results of three experiments on rANP(REA18) and two experiments on rANP. For rANP(REA18) there was four to fivefold lowering in the $K_m$, however, this was balanced by a 6–11-fold reduction in the turnover number, $k_{cat}$. The net result is that on average the catalytic efficiency ($k_{cat}/K_m$) of NEP for rANP(REA18) is decreased by 36% compared to rANP.

Aortic ring relaxation. The direct vasodilatory effects rANP and rANP(REA18) were compared in rat isolated aortic ring preparations to determine relative potency. Both native and

Table II. Basal Values of Parameters in Conscious Rats

<table>
<thead>
<tr>
<th>Parameter</th>
<th>rANP (0.25 µg/min) (n = 10)</th>
<th>rANP (0.325 µg/min) (n = 10)</th>
<th>rANP(REA18) (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW (grams)</td>
<td>346±5.7</td>
<td>336.4±4.3</td>
<td>344.7±9.0</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>122.5±3.4</td>
<td>122.2±3.9</td>
<td>128.1±3.5</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>393±10</td>
<td>384±9</td>
<td>389±6</td>
</tr>
<tr>
<td>UV ($µl/min$)</td>
<td>24.5±3.9</td>
<td>34.1±9.9</td>
<td>21.2±4.4</td>
</tr>
<tr>
<td>$U_{Na}V$ ($µmol/min$)</td>
<td>0.53±0.25</td>
<td>1.26±0.49</td>
<td>0.52±0.25</td>
</tr>
<tr>
<td>$U_{cGMP}V$ (pmol/min)</td>
<td>21.6±6.2</td>
<td>26.6±9.1</td>
<td>12.8±4.9</td>
</tr>
<tr>
<td>PcGMP (pmol/min)</td>
<td>5.9±0.7</td>
<td>5.1±0.5</td>
<td>6.7±1.5</td>
</tr>
</tbody>
</table>

Values are expressed as mean±SEM. BW, body weight; UV, urine volume; $U_{Na}V$, urinary sodium excretion; $U_{cGMP}V$, urinary cGMP excretion; PcGMP, plasma cGMP levels.

Figure 4. Concentration response for relaxation of phenylephrine contracted aortic rings. Percent relaxation is plotted as a function of peptide concentration (nM) for rANP (○) and rANP(REA18) (□). Values are expressed as mean±SEM (n = 4).

Figure 5. Monitoring the responses of MAP and HR to rANP and rANP(REA18) in conscious rats. *P < 0.05, comparison between the rANP (0.25 mg/min) group and other two groups. Changes (%) are expressed as infusion or recovery value minus control value, divided by control value. Values are expressed as mean±SEM, n = 10 for each group.
mutant rANP were equipotent in relaxing phenylephrine-contracted aortic rings, with an IC$_{50}$ of 1.3 nM (Fig. 4).

**Basal levels of parameters in conscious rats.** Surgery was performed in 32 rats, 2 of which were excluded from the study due to bleeding. Body weight in the included 30 rats was 342.6 ± 4.1 grams. At the end of the control period, i.e., after 30 min of saline infusion and before infusion of natriuretic peptides, there were no significant differences in the basal levels of MAP, HR, urine volume, urine sodium, urine cGMP, and plasma cGMP between the experimental groups (Table II).

**Effects of rANP or rANP(REA18) on MAP and HR.** Intra- venous infusion of rANP or rANP(REA18) significantly reduced MAP in conscious rats (Figs. 5 and 6, top). When both molecules were given at the same dose (0.25 μg/min), rANP(REA18) induced a significantly greater reduction in MAP than rANP at 10 and 20 min of the infusion period, and at 20 and 30 min of the recovery period (P < 0.05) (Fig. 5, top). The difference in MAP was not statistically significant at the end (30 min) of the infusion period (Figs. 5 and 6, top). At the end of the 30-min recovery period MAP had returned to baseline for rANP–treated rats whereas there continued to be significant depression of MAP with rANP(REA18). rANP at 0.325 μg/min and rANP(REA18) at 0.25 μg/min had identical effects on MAP for both the infusion and recovery periods (Figs. 5 and 6, top). Neither rANP nor rANP(REA18) altered HR significantly (Fig. 5, bottom).

**Urine volume and Na$^+$ excretion.** Both natriuretic peptides increased urine volume and urinary Na$^+$ excretion (Fig. 7, top and middle). rANP(REA18) (0.25 μg/min) significantly enhanced the diuretic response compared to rANP at the same dose (P < 0.05), and tended to enhance diuresis compared with rANP at the higher dose (0.325 μg/min) (P = 0.07) (Fig. 7, top). The natriuretic response to rANP(REA18) was significantly greater than that to rANP at the same dose (P < 0.05) as well as at the higher dose (P < 0.05) (Fig. 7, middle).

**cGMP responses.** rANP and rANP(REA18) markedly elevated plasma and urinary cGMP levels (Fig. 6 and 7, bottom). The elevation in the plasma level of cGMP in response to rANP(REA18) was enhanced compared to that to rANP at ei-
ther dose, but the difference was not statistically significant (Fig. 4, bottom). The rANP(REA18)-induced increase in urinary cGMP levels was significantly augmented as compared to that induced by rANP at the same dose for the infusion period (Fig. 7, bottom). The response of urinary cGMP excretion to rANP(REA18) was enhanced as compared to rANP at the higher dose. The difference, however, was statistically significant only for the recovery period and not for the infusion period.

**Discussion**

In the present study, we describe the development and pharmacological properties of a novel ANP analog that has reduced binding to rNPR-C and retains full agonist potency on rNPR-A. The need to develop a molecule specific for the rat was based on the observation that the hNPR-A selective ANP variant had reduced potency on the rat receptor (16). This is perhaps not surprising since both NPR-A and NPR-C show marked species-specific differences in pharmacology for a variety of ANP analogs (19, 22). In the case of the human receptors, combination of ANP mutations G9T, R11S, and G16R abolished NPR-C binding while retaining full agonist potency on human NPR-A (16). Competitive selection of ANP display phage libraries with the rat receptors identified the ANP mutant G16R, A17E, Q18A as the dominant rat NPR-A selective variant, with 180-200-fold reduced binding of rANP(REA18) to rat NPR-C. In comparison to the selection with the human receptors, no receptor selective mutations were obtained in ANP positions 9, 10, or 11. Thus in contrast to the selection with the human receptors, we identified only one region in rANP imparting reduced rNPR-C binding, and we did not have the option of combining mutations to abolish binding. The G16R mutation is common to the two experiments, but additional substitutions were also found at positions 17 and 18 when selected with the rat receptors. The specific role of each substitution in rANP(REA18) in reducing binding to rNPR-C remains to be determined.

Competition binding studies on the cloned rat receptors, combined with concentration–response stimulation of cGMP production, demonstrated that rANP(REA18) retained full agonist potency on rNPR-A compared with rANP. In relaxation experiments on precontracted rat aortic rings both molecules were indistinguishable. There is very close agreement between the potency of the two peptides in the stimulation of cGMP production with recombinant NPR-A (ED₅₀ = 1.8 nM) and in the relaxation of precontracted aortic rings (IC₅₀ = 1.3 nM), in agreement with the role of cGMP as a second messenger of endothelium-independent smooth muscle relaxation (6).

In contrast to the in vitro relaxation studies, rANP was less active than rANP(REA18) at eliciting a decrease in arterial pressure when infused into rats. The mechanisms for the depressor effect of ANP in intact animals are not entirely understood. In addition to the vasorelaxant effect of ANP, the fall in arterial pressure is, at least in part, due to a reduction in cardiac output resulting from a decrease in plasma volume (1). This decrease in plasma volume is ascribed to a shift of fluid from intra- to extravascular compartments (1). Inhibition of sympathetic outflow preventing a reflex adjustment to the diminished plasma volume may also be involved in the depressor response to ANP (28). Regardless of these mechanisms, the enhanced depressor effect of rANP(REA18) can be attributed to the reduced binding of rANP(REA18) to rNPR-C, which should lead to slower clearance and higher plasma concentrations compared to rANP. In vitro cell culture experiments and in vivo pharmacokinetic studies have described a role for NPR-C in ANP clearance and degradation. ANP bound to NPR-C is internalized at a rate faster than the hormonal off-rate, and is subsequently degraded in a lysosomal compartment prior to receptor recycling to the cell surface (29). When NPR-C is blocked in vivo with truncated ANP analogs that do not bind NPR-A there is a decrease in the metabolic clearance rate and in the steady-state volume of distribution for ANP, and an increase in the half life (17, 18). It is estimated that there is a 99% reserve of unoccupied NPR-C under normal conditions (17), providing a receptor reserve capable of hormonal buffering (13) during acute changes in plasma ANP concentrations. The simplest explanation for the increased response to rANP(REA18) may be pharmacokinetic given the role of NPR-C in ANP clearance. This, however, remains to be directly tested.

In addition to clearance mediated by NPR-C, there is also a clearance role for neutral endopeptidase as an extracellular protease for degradation of ANP (1, 16). To address the possibility of differential sensitivity of rANP and rANP(REA18) to proteolysis we measured the kinetic parameters of NEP on these two substrates. rANP(REA18) was only 36% more resistant to degradation than rANP as measured by the catalytic efficiency (k₅₀/K₉₅). It seems to be unlikely that the small reduction in NEP sensitivity significantly contributes to the enhanced renal effects of rANP(REA18). The magnitude of the reduced sensitivity to NEP, 36%, compared to the 180-200-fold reduction in NPR-C affinity suggests that the relative differences between rANP and rANP(REA18) in their in vivo properties derive primarily from receptor selectivity.

The increased activity of rANP(REA18) in eliciting a depressor effect on MAP is also manifest in increased renal responses, including urinary volume, sodium, and cGMP excretion. These effects are likely due to a higher effective concentration of rANP(REA18) as a result of reduced clearance. To determine if coexpression of NPR-A and NPR-C in the kidney attenuates responsiveness, we compared the renal response to an infusion of 0.25 μg/min rANP(REA18) to a higher dose of rANP (0.325 μg/min) that gave an equivalent decrease in MAP. We would expect the two molecules to have very similar plasma concentrations under these different doses. While the higher dose of rANP did result in an incremental but not significant increase in the renal response, rANP(REA18) at 0.25 μg/min still elicited a greater output of urine volume (P = 0.07) and urine sodium (P < 0.05).

The results of our experiments in conscious rats measuring vascular and renal responses demonstrate that rANP(REA18) is more active than rANP. When both molecules are administered at doses that produce equivalent depressor responses rANP(REA18) remains a more effective agonist of renal function. We interpret this observation to mean that decreased NPR-C binding leads to enhanced activity in eliciting a natriuretic and diuretic response. Cell culture experiments show that coexpression of NPR-A and NPR-C results in a shift in the ANP concentration response curve for cGMP production to higher values (16), suggesting that coexpression of these receptors in the glomerulus could have a similar effect. Another consideration is the potential role of NPR-C in reducing the concentration of ANP delivered to downstream sites in the re-
nal circulation. Hence nephron and collecting duct epithelial cells may also be exposed to higher concentrations of rANP(REA18) by virtue of not being cleared by glomerular NPR-C.

Our data are consistent with a specific role for NPR-C as a decoy receptor acting in local attenuation of ANP targeting to NPR-A in the kidney, resulting in a selectively decreased renal response to acute changes in plasma ANP. While this is not exclusive of a role for NPR-C in hormonal clearance through a large receptor reserve (12, 17, 18), one consequence will be that sites of receptor coexpression will exhibit relatively lower cGMP production from NPR-A due to a shift in the concentration response curve to higher ANP concentrations. NPR-A is expressed in the glomerulus and throughout the nephron, with highest levels in the glomerulus and inner medullary-collecting ducts (30–32). Despite the high levels of expression in the glomerulus, ANP stimulation of cGMP production is attenuated, with reports of reduced potency where ED$_{50} = 10–100$ nM (32) compared to ED$_{50} \sim 1$ nM for stimulation of cGMP on the cloned receptor.

Evidence of an enhanced renal response in the context of NPR-C blockade is also suggested in the results of Maack et al. (13), who first described a role for NPR-C in hormonal clearance and buffering. When the NPR-C-selective analog cANP$_{4-23}$ was coinfused with ANP in the isolated, perfused, rat kidney, these investigators observed a trend toward both increased potency (ED$_{50}$) and an increased maximal response for urinary sodium excretion (13). An analogous experiment has been described in vivo for coinfusion into rats of hANP and the analog hANP(9-Met) with an oxidized methionine at position 12 (33). This analog is more selective for NPR-C than NPR-A (19, 22, 33), and when coinfused with hANP there is a synergistic effect on diuresis (natriuresis was not measured) (33). For both of these experiments (13, 33) the selective blocking, or binding, of NPR-C by these ANP analogs resulted in an increased renal response during coinfusion with ANP, consistent with our proposed role for NPR-C as a decoy receptor attenuating renal NPR-A activation.

The decoy receptor hypothesis for renal NPR-C merits careful future investigation. A more direct test of this hypothesis will require detailed dose–response experiments on renal function and blood pressure effects. Measurement of pharmacokinetics and plasma levels of hormone will be required to ensure appropriate dosing comparisons. Furthermore, a potentially important test of this hypothesis will be in measurements of cGMP stimulation from isolated glomeruli.

Our data with rANP(REA18) suggest a model in which reduced NPR-C binding results in an enhanced renal response by increasing the available hormone concentration at NPR-A in the glomerulus, along with delivery of more ANP to postglomerular sites by the renal circulation. The net result is both enhanced diuresis and natriuresis compared to the depressor effect. The degree of the improved renal response, that is the therapeutic index, could be clinically significant considering that the hypotensive effect of ANP is dose limiting for renal efficacy (34). Receptor selective ANP variants may have improved activity over ANP for the treatment of acute renal failure and acute heart failure.

Acknowledgments

The authors thank Martin Struble and Kathryn Chan for peptide purification, Dr. Robert Bridenbaugh and K. MacFadden for purified recombinant NEP, Alan Padua for amino acid analysis, the Genentech DNA synthesis lab for oligonucleotides, Allison Bruce for artwork, and Kathie Ward for preparation of the manuscript.

References


